0.4631
price down icon5.91%   -0.0291
after-market Dopo l'orario di chiusura: .46 -0.0031 -0.67%
loading
Precedente Chiudi:
$0.4922
Aprire:
$0.5
Volume 24 ore:
352.80K
Relative Volume:
0.65
Capitalizzazione di mercato:
$18.08M
Reddito:
-
Utile/perdita netta:
$-117.67M
Rapporto P/E:
-0.1499
EPS:
-3.09
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
+17.84%
1M Prestazione:
+55.40%
6M Prestazione:
-16.56%
1 anno Prestazione:
-85.97%
Intervallo 1D:
Value
$0.4381
$0.5074
Intervallo di 1 settimana:
Value
$0.40
$0.5074
Portata 52W:
Value
$0.2195
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Nome
Athira Pharma Inc
Name
Telefono
(425) 620-8501
Name
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Dipendente
26
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-07
Name
Ultimi documenti SEC
Name
ATHA's Discussions on Twitter

Confronta ATHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.4631 19.22M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-19 Downgrade Mizuho Outperform → Neutral
2024-09-04 Downgrade BTIG Research Buy → Neutral
2024-09-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 Downgrade Rodman & Renshaw Buy → Neutral
2024-08-19 Iniziato Rodman & Renshaw Buy
2022-10-17 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 Iniziato Mizuho Buy
2022-06-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 Downgrade Jefferies Buy → Hold
2022-06-23 Downgrade Stifel Buy → Hold
2022-05-10 Iniziato BTIG Research Buy
2022-04-21 Iniziato Berenberg Buy
2021-12-15 Iniziato Goldman Neutral
2020-10-13 Iniziato Goldman Buy
2020-10-13 Iniziato JMP Securities Mkt Outperform
2020-10-13 Iniziato Jefferies Buy
2020-10-13 Iniziato Stifel Buy
Mostra tutto

Athira Pharma Inc Borsa (ATHA) Ultime notizie

pulisher
Jul 24, 2025

Is Athira Pharma Inc. a good long term investmentRapidly growing investment returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Athira Pharma Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Athira Pharma Inc. stock priceHigh-yield capital appreciation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Athira Pharma Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World

Jul 23, 2025
pulisher
Jul 17, 2025

Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView

Jul 17, 2025
pulisher
Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why Athira Pharma Inc. stock attracts strong analyst attentionHigh Accuracy Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Athira Pharma Inc. stock performs during market volatilityDouble Profit With Half Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Athira Pharma Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 10, 2025
pulisher
Jun 25, 2025

Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 05, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire

Jun 04, 2025
pulisher
Jun 03, 2025

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 03, 2025
pulisher
Jun 02, 2025

Athira Pharma Holds Annual Stockholders Meeting - TipRanks

Jun 02, 2025
pulisher
Jun 01, 2025

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 01, 2025
pulisher
May 27, 2025

This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance

May 27, 2025
pulisher
May 20, 2025

Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com

May 20, 2025
pulisher
May 15, 2025

Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Athira Pharma Reports Reduced Losses and Strategic Focus - MSN

May 14, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times

May 09, 2025
pulisher
May 08, 2025

Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World

May 08, 2025
pulisher
May 07, 2025

Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

May 06, 2025
pulisher
Apr 29, 2025

Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Apr 29, 2025
pulisher
Apr 24, 2025

ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025

Athira Pharma Inc Azioni (ATHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):